Taken together, the above studies suggest that treatment with
oral PLE together with NB-UVB may improve repigmentation
in patients with vitiligo; however, larger trials are warranted to
confirm these observations.
PLE and Psoriasis Vulgaris
De las Heras et al,25 in 1997 sought to evaluate the effect of oral
PLE as an adjuvant treatment to PUVA for patients with plaque
psoriasis; they found that patients who received PLE in addition
to PUVA had a statistically significant decrease in cumulative
dosage of PUVA required for clearance (P<0.0001), whereas
there was no difference regarding the number of UVA sessions
required. Histochemically, they observed the preservation of
epidermal CD1a+ dendritic cells in patients who had been treated
with oral PLE in addition to PUVA. These results suggest that
the addition of oral PLE to PUVA could potentially minimize the
adverse effects seen with PUVA photochemotherapy, namely
local immunosuppression and photocarcinogenesis.
Additionally, Middlekamp-Hup et al,26 demonstrated that oral
PLE significantly decreased the acute PUVA-induced phototoxic
reaction and also diminished the subsequent cutaneous
pigmentary response. By reducing the hyperpigmentation,
the need for increasing the UVA dose was also reduced, thus
leading to a lower cumulative UVA dose for clearance of psoriasis.
Histologically, they showed that in patients treated with
oral PLE and PUVA, there was a significantly lower number of
sunburn cells (P=0.05) and less depletion of Langerhans cells
(P≤0.01) when compared to skin treated with PUVA alone, confirming
oral PLE’s effectiveness as a chemopreventative agent
against PUVA-induced phototoxicity.
PLE and Atopic Dermatitis
A study by Ramirez-Bosca et al,27 sought to investigate whether
daily treatment with PLE would reduce the use of topical corticosteroids
in children and adolescents with moderate atopic
dermatitis, in which disease severity was evaluated using the
Scoring Atopic Dermatitis (SCORAD) index. They enrolled 105
participants, aged 2-17 years, to a randomized, double-blinded,
placebo-controlled trial. The patients were randomized to
receive, in addition to their standard treatment, either PLE or placebo
for 6 months. Patients were divided into 3 treatment groups
according to age, such that children aged 6 years or younger received
240mg daily of PLE, children aged 6 to 12 years received
360mg daily (120 mg in the morning and 240 mg at night), and
children over 12 years old received 480mg daily in 2 divided
doses. The authors found that subjects in the PLE group demonstrated
a reduction in topical corticosteroid use from the first
month to second month, and from the fourth month to the fifth
month (P=0.012). More notably, they found an overall decrease
in oral antihistamine use in the PLE group after the first month of
treatment, and this finding became statistically significant after
the third month of treatment with PLE (P=0.038). Clinically, the
authors found a reduction in the number of flares reported by
PLE group, however this was not statistically significant. These
results indicate that long-term administration of oral PLE, in addition
to standard first-line therapy, may have a beneficial effect
in the treatment of atopic dermatitis. Again, more studies are
needed, however, to confirm these benefits.
PLE and Infectious Diseases
PLE has also been investigated for its effect on infectious processes,
particularly in athletes regularly engaged in rigorous
physical activity (volleyball, football, athletics, cycling) who
may be predisposed to a window of immunosuppression after
strenuous activity. In 2012, Solivellas et al,28 conducted
an observational study in which they enrolled two groups
of patients, of which one group received 480mg PLE twice
daily for 3 months and the other did not receive PLE. They
subsequently compared the onset of respiratory infection
and relapse infection rates in both groups. The participants
were followed for a total of 8 months. The authors found that
symptomatic improvement was reached quicker, was more
favorable in the PLE group, and fewer relapse cases were
found in this group as well. The authors attributed this effect
to the anti-inflammatory and immunomodulatory properties
of PLE; specifically, its ability to stimulate peripheral blood
mononuclear cells and its effect on cytokines such as an increase
in interleukin-2 (IL-2), IL-10, and interferon-α secretion,
and a decrease in tumor necrosis factor (TNF) γ levels.29 Additionally,
PLE regulates the expression of adhesion molecules
on monocytes and lymphocytes and increases membrane
antigen expression on T cells and natural killer cells.30 These
changes suggest possible augmentation of cell-mediated immunity,
especially against viruses.
CONCLUSION
Oral PLE has been used in the treatment of dermatologic disease
with promising results and no reported side effects. It has
multiple mechanisms of action, ranging from anti-inflammatory
and immunomodulatory to antioxidative and photoprotective.